By analysis of the mutational spectrum, DNA methylation patterns, chromosomal aberrations, and proteome profiles of tumor tissues from glioblastoma patients with O6-methylguanine DNA-methyltransferase (MGMT) promoter methylation and response (>15 months progression-free-survival) vs. patients with no response (<6 months) to combined radiochemotherapy with temozolomide, we aim to identify novel predictive tissue-biomarkers for temozolomide response and resistance in glioblastoma patients. These novel predictive markers are expected to have a direct impact on clinical decision making with improved predictive power when compared to MGMT methylation status alone. The visual abstract below shows the aims and planned tasks of the work package.
Based on the findings of work package A05 there was a shift in reserach focus for the second funding period. The follow-up project aims at in depth characterization of the unusual EGFR-fusions identified in long term survivors using state-of-the-art mass-spectrometry based proeteomics and interactomics (C06).